Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer Pharmaceutical Business ReviewThis combo is approved for adults with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer.OncologyRead full story pharminent September 7, 2026 (Last updated: September 9, 2026) Pharmaceutical Business Review This combo is approved for adults with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer. Oncology Read full story Post navigation Previous: Major trial of Roche Alzheimer’s drug kicks off in EuropeNext: Novartis hit as Lp(a) drug fails cardio outcomes trial Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026